Eyepoint's wet AMD therapy misses key endpoint in trial
Eyepoint's experimental treatment for wet age-related macular degeneration failed to show that patients could maintain vision with fewer injections than standard therapy. The company says it still believes the drug has potential.
Related stories
LSD-based treatment shows promise for generalized anxiety disorder in late-stage trial · Mental health
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise.” Browse more stories.